Statement: There is 1 case (1.45%) of thrombocytopenia in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 26/69 (37.68%)   Thrombophlebitis * 1/69 (1.45%)   Anaemia NOS * 1/69 (1.45%)   Acute febrile neutrophilic dermatosis * 1/69 (1.45%)   Cardiac failure NOS * 2/69 (2.90%)   Ejection fraction decreased * 1/69 (1.45%)   Intestinal obstruction NOS * 1/69 (1.45%)   Diarrhoea NOS * 2/69 (2.90%)   Febrile neutropenia * 12/69 (17.39%)   Mucosal inflammation NOS * 1/69 (1.45%)